Our results indicate that aberrant midline crossing by motor neuron cell bodies and axons in mice lacking Robo1 and Robo2 are not interdependent and that DCC contributes to axon, but not cell body ...

Lexeo Therapeutics, Inc, a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced positive interim data across all dose cohorts of ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on outcomes the biotech plans to use as co-primary endpoints in a ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood —and for the hundreds of Canadians who live with it, the lack of ...

At the 2025 AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential ...

Sarepta and Roche are hoping after the independent DMC review that it will be able to continue dosing in the three studies. Image credit: Shutterstock / Andrii Yalanskyi. Sarepta Therapeutics and ...

We found that mice lacking cystatin B develop myoclonic seizures and ataxia, similar to symptoms seen in the human disease. The principal cytopathology appears to be a loss of cerebellar granule ...

Extra spacing between teeth is very common among young children. Midline diastemas occur in approximately 98% of 6-year-olds, 49% of 11-year-olds, and 7% of 12–18-year-olds. For adults, the estimates ...

Bill Nye "The Science Guy", renowned science educator and television personality, was a guest speaker at the National Ataxia Foundation’s Annual Ataxia Conference in Las Vegas on Saturday.

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults with type 2 diabetes. A regulatory decision is anticipated in 2025. Rybelsus, ...

Motorists with certain health conditions are being warned to notify the Driver and Vehicle Licensing Agency (DVLA) of their diagnosis, otherwise they could be facing a £1000 fine. The government ...